Skip to content
Delayed ~15 min

BDTX BLACK DIAMOND THERAPEUTICS INC

Permanent stock page ↗

Health Care · Russell 2000

Next earnings: not announced yet

What 10 analyst firms say about BLACK DIAMOND THERAPEUTICS INC: their latest ratings, price targets and how far the stock is from them. How it works

1.74 USD+0.08 (+4.52%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+431.1%to the avg target 9.21 USD+7.48 USD
Buy 7 · Hold 2 · Sell 0

9 rated views · 10 analyst/firm records · 10 firms

Latest report29 Oct 2026avg report date 24 Jul
Target rangePrice is below every target

Radar score

  • Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
  • Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD

Recent analyst activity · last 90 days

Our tracked history has 3 reports on BDTX from 3 analyst firms in the last 90 days (11 firms in the past year).

Comparing each firm's latest target with its previous one: 1 left it unchanged and 1 has its first observed target in the past year.

No firm's latest available rating differs from its previous one.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
Freedom Capital MarketsIlya ZubkovBuy10 Aug 20268.00 USD
GuggenheimBradley P CaninoHold1 Jul 2026—
H.C. WainwrightRobert BurnsBuy29 Oct 202611.00 USD
JefferiesFarzin HaqueBuy6 Aug 202610.00 USD
Piper SandlerKelsey GoodwinBuy5 Aug 20268.00 USD
Raymond JamesSean MccutcheonBuy6 Aug 202611.00 USD
TD CowenUnnamed analystBuy6 Aug 2026—
WedbushRobert DriscollBuy6 Aug 202614.00 USD
Weiss RatingsUnnamed analyst—9 Oct 2026—
Data feed RESEARCHResearch TeamHold6 Feb 20262.50 USD

Partial coverage · checked 6 Nov (6 Nov 2026, 03:45 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.